CenTrial Logo

Chagas Disease Treatment: A Breakthrough Clinical Trial Reveals Promising Results


Clinical trial shows shorter treatment for Chagas disease is effective

Chagas disease, caused by the parasite Trypanosoma cruzi, affects millions worldwide, particularly in Latin America. Benznidazole is a key medication, but its effectiveness and side effects have posed challenges. However, a groundbreaking trial, the MULTIBENZ trial, sheds light on new treatment approaches.

Clinical Trial

The MULTIBENZ trial, conducted across Argentina, Brazil, Colombia, and Spain, focused on adults with chronic Chagas disease. Researchers aimed to compare three benznidazole regimens to enhance both effectiveness and safety.

Participants were randomly assigned to one of three groups: a control group receiving the standard 300 mg/day dose for 60 days, a low-dose group receiving 150 mg/day for 60 days, or a short treatment group receiving 400 mg/day for just 15 days. The trial tracked outcomes over a 12-month follow-up period.


The results showed that while all groups exhibited similar rates of sustained parasite clearance, the short-treatment group demonstrated comparable efficacy to the standard regimen. This suggests that a significantly shorter treatment duration could yield the same benefits while potentially improving adherence and expanding treatment accessibility.

Concerns regarding treatment safety were also addressed. Despite similar rates of adverse events across groups, the short treatment regimen led to fewer treatment discontinuations compared to the standard regimen. This indicates that while side effects may occur, they are manageable, and shorter treatment courses may mitigate treatment interruptions.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


The implications of this trial are profound. By offering a shorter, equally effective treatment option, healthcare providers can enhance patient adherence and potentially reach more individuals in need. However, further research, particularly in larger phase 3 clinical trials, is necessary to validate these findings and solidify their integration into clinical practice.


The MULTIBENZ trial represents a significant step forward in Chagas disease treatment. By optimizing benznidazole regimens, we can strive toward more accessible, effective, and safer treatments for this debilitating disease. This trial underscores the importance of ongoing research and collaboration in improving global health outcomes.


The Lancet, Jan-10-24
ClinicalTrials.gov, NCT03191162
About Chagas Disease

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.